Docstoc

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inhibitex, Inc

Document Sample
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inhibitex, Inc Powered By Docstoc
					Pomerantz Law Firm Investigates Claimson Behalf
of Investors of Inhibitex, Inc.
January 09, 2012 04:04 PM Eastern Time 

NEW YORK--(EON: Enhanced Online News)--Pomerantz Haudek Grossman & Gross LLP is investigating claims
on behalf of investors of Inhibitex, Inc. (“Inhibitex” or the “Company”) (NASDAQ:INHX) concerning the proposed
acquisition of Inhibitex by Bristol-Myers Squibb Company (“Bristol-Myers”) in a cash transaction valued at
approximately $2.5 billion.

The investigation concerns whether the Inhibitex directors are breaching their fiduciary duties by failing to adequately
shop the Company and maximize shareholder value. Through the acquisition, Bristol-Meyer stands to gain a very
lucrative position in the Hepatitis C drug industry at a time when it is losing patent protection on three of its four top
selling drugs. Under the terms of the agreement shareholders would receive $26.00 per share - at least one analyst
has set a target price of $34.00 per share.

Inhibitex shareholders seeking more information about this acquisition are advised to contact Gustavo Bruckner,
Esq. at gfbruckner@pomlaw.com or 212-661-1100 or toll free at 888-476-6529, ext. 302. Shareholders may also
contact Rachelle R. Boyle at rrboyle@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 237.

The Pomerantz Firm, with offices in New York, Chicago, and Washington, D.C., is acknowledged as one of the
premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class
actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the
rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has
recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Contacts
Pomerantz Haudek Grossman & Gross LLP
Rebecca Jarmon, 212-661-1100 ext. 314
rjarmon@pomlaw.com

Recent Stories from Pomerantz Haudek Grossman & Gross LLP
    l   Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cogdell Spencer Inc.
        December 27, 2011
        NEW YORK--(EON: Enhanced Online News)--Pomerantz Haudek Grossman & Gross LLP is investigating
        claims on behalf of investors of Cogdell Spencer Inc. (“Cogdell” or the “Company”) (NYSE:CSA) conce...
        more »
    l   Pomerantz Law Firm Investigates Claims on Behalf of Investors of WCA Waste Corporation
        December 22, 2011
        NEW YORK--(EON: Enhanced Online News)--Pomerantz Haudek Grossman & Gross LLP is investigating
        claims on behalf of investors of WCA Waste Corporation (“WCA” or the “Company”) (NASDAQ:WCAA)
        conce... more »
    l   Pomerantz Law Firm Investigates Claims on Behalf of Investors of Delphi Financial Group
        December 21, 2011
        NEW YORK--(EON: Enhanced Online News)--Pomerantz Haudek Grossman & Gross LLP is investigating
        claims on behalf of investors of Delphi Financial Group (“Delphi” or the “Company”) (NASDAQ:DFG) co...
        more »

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:6
posted:1/9/2012
language:
pages:2
Description: NEW YORK--(EON: Enhanced Online News)--Pomerantz Haudek Grossman & Gross LLP is investigating claims on behalf of investors of Inhibitex, Inc. (“Inhibitex” or the “Company”) (NASDAQ:INHX) concerning the proposed acquisition of Inhibitex by Bristol-Myers Squibb Company (“Bristol-Myers”) in a cash transaction valued at approximately $2.5 billion. The investigation concerns whether the Inhibitex directors are breaching their fiduciary duties by failing to adequately shop the Company and maximiz a style='f
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.